[Cis-platinum in the treatment of disseminated testicular neoplasms resistant to classical chemotherapy].
Seven patients with advanced testicular tumors, resistant to existing chemotheurapeutic agents, were treated with a new antitumor agent, the Cisplatinum (associated to mannitol induced hyperdiuresis). There were 3 objective remissions (1 complete and 2 partial). Major toxicity was gastrointestinal. There was little renal and hematologic toxicity in our serie. The drug may have use in combination therapy in advanced non seminomatous testicular tumors.
D000328:Adult; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D004407:Dysgerminoma / Q000188:drug therapy*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D009362:Neoplasm Metastasis; D013724:Teratoma / Q000188:drug therapy*; D013736:Testicular Neoplasms / Q000188:drug therapy*
D002945:Cisplatin
Le cisplatinum dans le traitement du cancer du testicule disséminé et résistant à la chimiothérapie classique.